Teruaki Matsui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teruaki Matsui has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Komei Ito
Department of Allergy, Allergy and Immunology Center Aichi Children's Health and Medical Center Obu Japan
21 shared publications - Shiro Sugiura
Department of Allergy, Allergy and Immunology Center Aichi Children's Health and Medical Center Obu Aichi Japan
17 shared publications Komei Ito
Aichi Children´s Health and Medical Center
13 shared publicationsShiro Sugiura
Aichi Children’s Health and Medical Center
11 shared publications- Katsumasa Kitamura
Department of Allergy, Allergy and Immunology Center Aichi Children's Health and Medical Center Obu Japan
10 shared publications Naoyuki Kando
Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan
10 shared publications
Latest Publications
- 7 May 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (9) , 1107-1109
Fixed Very‐Low‐Dose Oral Immunotherapy in Infants and Toddlers With Low‐Threshold Egg, Milk or Wheat Allergy: A Prospective Cohort Study
Summary: Fixed very‐low‐dose oral immunotherapy improved 2 g OFC outcomes compared with avoidance. Reactions were rare and mild, with no adrenaline‐treated anaphylaxis and fewer accidental reactions than avoidance.
- 7 May 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (9) , 1107-1109
Fixed Very‐Low‐Dose Oral Immunotherapy in Infants and Toddlers With Low‐Threshold Egg, Milk or Wheat Allergy: A Prospective Cohort Study
Summary: Fixed very‐low‐dose oral immunotherapy improved 2 g OFC outcomes compared with avoidance. Reactions were rare and mild, with no adrenaline‐treated anaphylaxis and fewer accidental reactions than avoidance.
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Current practices of topical and systemic novel molecular-targeted therapies for pediatric atopic dermatitis in Japan: A nationwide survey of physicians providing pediatric allergy care
Background: The availability of new topical molecular-targeted therapies, biologics, and oral Janus kinase (JAK) inhibitors has expanded treatment options for pediatric atopic dermatitis (AD). However, real-world prescribing patterns, rationale for use, and challenges in clinical decision-making remain unclear. This study aimed to characterize contemporary management practices and identify barriers to optimal therapy among physicians providing pediatric allergy care in Japan. Methods: We conducted a nationwide, cross-sectional, anonymous online survey of members of the Japanese Society of Pediatric Allergy and Immunology from July 2025 to August 2025. The questionnaire, developed by AD specialists, captured physician characteristics, treatment strategies, utilization of topical and systemic agents, adverse events, and perceived difficulties in clinical practice. Descriptive statistics were used to summarize responses. Results: A total of 488 physicians participated. Most were experienced pediatric specialists who reported high adherence to AD guidelines and frequent use of proactive therapy. Difamilast and delgocitinib were widely used among topical nonsteroidal agents. Biologics had been prescribed by 65.6% of respondents and oral JAK inhibitors by 36.1%, although substantial caution was observed. Safety was the primary factor guiding selection between biologics and JAK inhibitors. Many physicians reported difficulty determining appropriate discontinuation timing for systemic therapies. Conclusions: Japanese pediatric allergy physicians actively employ novel topical and systemic therapies but face persistent uncertainty regarding long-term management and treatment discontinuation. Strengthening standardized topical care, clarifying exit strategies for systemic therapy, and enhancing long-term safety data are essential to optimize pediatric AD management.
- 10 March 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Open AccessCurrent practices of topical and systemic novel molecular-targeted therapies for pediatric atopic dermatitis in Japan: A nationwide survey of physicians providing pediatric allergy care
Background: The availability of new topical molecular-targeted therapies, biologics, and oral Janus kinase (JAK) inhibitors has expanded treatment options for pediatric atopic dermatitis (AD). However, real-world prescribing patterns, rationale for use, and challenges in clinical decision-making remain unclear. This study aimed to characterize contemporary management practices and identify barriers to optimal therapy among physicians providing pediatric allergy care in Japan. Methods: We conducted a nationwide, cross-sectional, anonymous online survey of members of the Japanese Society of Pediatric Allergy and Immunology from July 2025 to August 2025. The questionnaire, developed by AD specialists, captured physician characteristics, treatment strategies, utilization of topical and systemic agents, adverse events, and perceived difficulties in clinical practice. Descriptive statistics were used to summarize responses. Results: A total of 488 physicians participated. Most were experienced pediatric specialists who reported high adherence to AD guidelines and frequent use of proactive therapy. Difamilast and delgocitinib were widely used among topical nonsteroidal agents. Biologics had been prescribed by 65.6% of respondents and oral JAK inhibitors by 36.1%, although substantial caution was observed. Safety was the primary factor guiding selection between biologics and JAK inhibitors. Many physicians reported difficulty determining appropriate discontinuation timing for systemic therapies. Conclusions: Japanese pediatric allergy physicians actively employ novel topical and systemic therapies but face persistent uncertainty regarding long-term management and treatment discontinuation. Strengthening standardized topical care, clarifying exit strategies for systemic therapy, and enhancing long-term safety data are essential to optimize pediatric AD management.
- 2 February 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (2) , e70291
Proteomic approach to investigate allergens involved in severe walnut allergy
Background: Despite the increasing prevalence of walnut allergy (WA), no allergen components have been established as markers of disease severity. This study aimed to identify proteins specifically associated with severe WA in children. Methods: We analyzed 48 children aged 3.4–16 years who underwent an oral food challenge to walnut between February 2019 and March 2022. Children with positive and negative reactions were categorized into a WA group and walnut sensitization (WS) group, respectively. The dose‐adjusted reaction severity of WA patients was quantified using the Anaphylaxis Scoring Aichi's total score divided by the cumulative protein dose that induced symptoms (TS/Pro). Using the median TS/Pro value in all cases of the WA group as a cut‐off, 11 of 21 WA patients with stored sera were classified as high TS/Pro (TS/Pro ≥154.1); the remaining 10 patients were classified as low TS/Pro. Immunoblotting, mass spectrometry, and enzyme‐linked immunosorbent assay (ELISA) were used to identify candidate markers of WA severity. Results: Jug r 1‐specific IgE (sIgE) levels were higher in the WA group, but were not significantly associated with TS/Pro. Immunoblotting and mass spectrometry detected phospholipase D alpha 1 (PLDa1) in 5/11 (45.5%) high TS/Pro patients and 1/10 (10%) low TS/Pro patients ( p = .149). ELISA with recombinant PLDa1 confirmed similar results. Moreover, the absorbance of recombinant PLDa1‐sIgE was significantly correlated with TS/Pro ( ρ = 0.47, p = .032). Conclusions: PLDa1 (Jug r 9) is a candidate marker of WA severity. The early identification of children at risk of severe WA may aid clinicians in optimizing their management strategies.
- 2 February 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (2) , e70291
Proteomic approach to investigate allergens involved in severe walnut allergy
Background: Despite the increasing prevalence of walnut allergy (WA), no allergen components have been established as markers of disease severity. This study aimed to identify proteins specifically associated with severe WA in children. Methods: We analyzed 48 children aged 3.4–16 years who underwent an oral food challenge to walnut between February 2019 and March 2022. Children with positive and negative reactions were categorized into a WA group and walnut sensitization (WS) group, respectively. The dose‐adjusted reaction severity of WA patients was quantified using the Anaphylaxis Scoring Aichi's total score divided by the cumulative protein dose that induced symptoms (TS/Pro). Using the median TS/Pro value in all cases of the WA group as a cut‐off, 11 of 21 WA patients with stored sera were classified as high TS/Pro (TS/Pro ≥154.1); the remaining 10 patients were classified as low TS/Pro. Immunoblotting, mass spectrometry, and enzyme‐linked immunosorbent assay (ELISA) were used to identify candidate markers of WA severity. Results: Jug r 1‐specific IgE (sIgE) levels were higher in the WA group, but were not significantly associated with TS/Pro. Immunoblotting and mass spectrometry detected phospholipase D alpha 1 (PLDa1) in 5/11 (45.5%) high TS/Pro patients and 1/10 (10%) low TS/Pro patients ( p = .149). ELISA with recombinant PLDa1 confirmed similar results. Moreover, the absorbance of recombinant PLDa1‐sIgE was significantly correlated with TS/Pro ( ρ = 0.47, p = .032). Conclusions: PLDa1 (Jug r 9) is a candidate marker of WA severity. The early identification of children at risk of severe WA may aid clinicians in optimizing their management strategies.
- Open Access
- 14 January 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 16 (4) , 240-243
Anaphylaxis caused by mustard in children: A case report from Japan
Despite reports in Western countries, mustard allergy is rarely acknowledged in Japan. Here, we present the case of a 4-year-old girl without previous allergies who developed anaphylaxis after eating a hot dog containing mustard and required intramuscular epinephrine administration. ImmunoCAP testing revealed mustard-specific immunoglobulin E (6.72 kUA/L), and the skin prick test was strongly positive to yellow mustard, oriental mustard, and processed mustard products. Oral food challenge (OFC) with 10 mg mustard (approximately 0.4 mg mustard protein) provoked vomiting. Therefore, she was diagnosed with mustard allergy. Two-dimensional western blot analysis and mass spectrometry led to the identification of 12 proteins from 10 immunoglobulin E (IgE)-binding spots; however, none corresponded to known mustard allergens (Sin a 1–4). Notably, spot 7 exhibited significant IgE-binding but remained unidentified, suggesting potential novel allergens. This is the first documented case of mustard allergy in Japan verified with OFC, highlighting both the risk of severe reactions at minimal doses and the importance of OFC for diagnosis. Further studies using recombinant allergens are warranted to validate the clinical relevance of the newly identified proteins in the present case.
- 14 January 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 16 (4) , 240-243
Open AccessAnaphylaxis caused by mustard in children: A case report from Japan
Despite reports in Western countries, mustard allergy is rarely acknowledged in Japan. Here, we present the case of a 4-year-old girl without previous allergies who developed anaphylaxis after eating a hot dog containing mustard and required intramuscular epinephrine administration. ImmunoCAP testing revealed mustard-specific immunoglobulin E (6.72 kUA/L), and the skin prick test was strongly positive to yellow mustard, oriental mustard, and processed mustard products. Oral food challenge (OFC) with 10 mg mustard (approximately 0.4 mg mustard protein) provoked vomiting. Therefore, she was diagnosed with mustard allergy. Two-dimensional western blot analysis and mass spectrometry led to the identification of 12 proteins from 10 immunoglobulin E (IgE)-binding spots; however, none corresponded to known mustard allergens (Sin a 1–4). Notably, spot 7 exhibited significant IgE-binding but remained unidentified, suggesting potential novel allergens. This is the first documented case of mustard allergy in Japan verified with OFC, highlighting both the risk of severe reactions at minimal doses and the importance of OFC for diagnosis. Further studies using recombinant allergens are warranted to validate the clinical relevance of the newly identified proteins in the present case.
- 2 January 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (1) , e70274
Factors associated with false negative exercise provocation tests following exercise‐induced allergic reactions in children desensitized to wheat
Background: The frequency of false negatives in exercise provocation tests (EPTs) when evaluating exercise‐induced allergic reactions on desensitization (EIARD) remains unclear. This study aimed to determine the frequency of allergic symptom induction after a negative EPT result in patients at risk of EIARD and to identify its associated factors. Methods: This retrospective cohort study analyzed 109 patients aged 5–18 years who underwent EPTs between February 2012 and March 2023 to assess EIARD after wheat oral immunotherapy (OIT). EPT was performed in all cases after rush OIT and in high‐risk cases after slow OIT. Patients with a negative/indeterminate EPT result were monitored for 1 year. Individuals who developed allergic reactions during exercise after wheat ingestion were categorized as “Event+” and were regarded as having false‐negative EPT results. Patients without events were categorized as “Event−”. Candidate factors between the Event+ and Event− groups were compared using nonparametric statistical tests. Results: Among 53 patients with negative/indeterminate EPT results, 14 (26.4%) experienced allergic symptoms during follow‐up (Event+ group). Higher ω5‐gliadin‐specific IgE levels at the time of EPT were significantly associated with Event+. No other factors (i.e., age, sex, allergy severity, or exercise intensity) showed any association. All Event+ cases occurred outdoors, suggesting a possible influence of environmental factors. Conclusion: False negatives occurred in 26.4% of pediatric wheat‐desensitized patients with EPTs. Our findings highlight the need to periodically monitor EIARD after negative EPT results. Future studies should explore methods to improve the accuracy of EPTs and identify predictive markers of EIARD risk.
- 2 January 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (1) , e70274
Factors associated with false negative exercise provocation tests following exercise‐induced allergic reactions in children desensitized to wheat
Background: The frequency of false negatives in exercise provocation tests (EPTs) when evaluating exercise‐induced allergic reactions on desensitization (EIARD) remains unclear. This study aimed to determine the frequency of allergic symptom induction after a negative EPT result in patients at risk of EIARD and to identify its associated factors. Methods: This retrospective cohort study analyzed 109 patients aged 5–18 years who underwent EPTs between February 2012 and March 2023 to assess EIARD after wheat oral immunotherapy (OIT). EPT was performed in all cases after rush OIT and in high‐risk cases after slow OIT. Patients with a negative/indeterminate EPT result were monitored for 1 year. Individuals who developed allergic reactions during exercise after wheat ingestion were categorized as “Event+” and were regarded as having false‐negative EPT results. Patients without events were categorized as “Event−”. Candidate factors between the Event+ and Event− groups were compared using nonparametric statistical tests. Results: Among 53 patients with negative/indeterminate EPT results, 14 (26.4%) experienced allergic symptoms during follow‐up (Event+ group). Higher ω5‐gliadin‐specific IgE levels at the time of EPT were significantly associated with Event+. No other factors (i.e., age, sex, allergy severity, or exercise intensity) showed any association. All Event+ cases occurred outdoors, suggesting a possible influence of environmental factors. Conclusion: False negatives occurred in 26.4% of pediatric wheat‐desensitized patients with EPTs. Our findings highlight the need to periodically monitor EIARD after negative EPT results. Future studies should explore methods to improve the accuracy of EPTs and identify predictive markers of EIARD risk.
- 10 December 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (12) , e70254
Exploration of severity‐associated peanut allergens via proteomic analysis
Background: The relationship between the severity of peanut allergy and component‐specific immunoglobulin E (IgE) remains partially analyzed. We aimed to explore this relationship using a proteomic analysis of pediatric patients with peanut allergy. Methods: Immunoblotting and mass spectrometry were used to identify candidate peanut allergen components, which were confirmed via enzyme‐linked immunosorbent assay using sera from pediatric patients with peanut allergy confirmed through a positive oral food challenge test (OFC). The association between each protein‐specific IgE level and the severity of peanut allergy was compared. The severity of peanut allergy was quantified as TS/Pro, which is the total score (TS) of Anaphylaxis Scoring Aichi divided by the cumulative protein dose of peanuts at the OFC (Pro). Results: This study comprised 52 patients with peanut allergy. In addition to the known peanut allergen components, we discovered seven allergens in more than five participants. Among the participants, 24 (46.2%) had Annexin Gh1‐specific IgE. Ara h 2 ( r s = 0.67, p < .001) and Ara h 6 ( r s = 0.66, p < .001) specific IgEs and the sum of the absorbance of all seven candidates ( r s = 0.64, p < .001) were strongly correlated with TS/Pro. Ara h 1 ( r s = 0.30, p < .05), Ara h 3 (rs = 0.37, p < .01), Ara h 7 ( r s = 0.34, p < .05), and the seed biotin‐containing protein SBP65 ( r s = 0.35, p < .05) specific IgEs were correlated with TS/Pro. Conclusion: Ara h 2‐ and 6‐specific IgEs and sensitization diversity were the most significant factors that correlated with peanut allergy severity. We identified SBP65 (Ara h 20) as a potential novel allergen component related to peanut allergy severity.
- 10 December 2025
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (12) , e70254
Exploration of severity‐associated peanut allergens via proteomic analysis
Background: The relationship between the severity of peanut allergy and component‐specific immunoglobulin E (IgE) remains partially analyzed. We aimed to explore this relationship using a proteomic analysis of pediatric patients with peanut allergy. Methods: Immunoblotting and mass spectrometry were used to identify candidate peanut allergen components, which were confirmed via enzyme‐linked immunosorbent assay using sera from pediatric patients with peanut allergy confirmed through a positive oral food challenge test (OFC). The association between each protein‐specific IgE level and the severity of peanut allergy was compared. The severity of peanut allergy was quantified as TS/Pro, which is the total score (TS) of Anaphylaxis Scoring Aichi divided by the cumulative protein dose of peanuts at the OFC (Pro). Results: This study comprised 52 patients with peanut allergy. In addition to the known peanut allergen components, we discovered seven allergens in more than five participants. Among the participants, 24 (46.2%) had Annexin Gh1‐specific IgE. Ara h 2 ( r s = 0.67, p < .001) and Ara h 6 ( r s = 0.66, p < .001) specific IgEs and the sum of the absorbance of all seven candidates ( r s = 0.64, p < .001) were strongly correlated with TS/Pro. Ara h 1 ( r s = 0.30, p < .05), Ara h 3 (rs = 0.37, p < .01), Ara h 7 ( r s = 0.34, p < .05), and the seed biotin‐containing protein SBP65 ( r s = 0.35, p < .05) specific IgEs were correlated with TS/Pro. Conclusion: Ara h 2‐ and 6‐specific IgEs and sensitization diversity were the most significant factors that correlated with peanut allergy severity. We identified SBP65 (Ara h 20) as a potential novel allergen component related to peanut allergy severity.
- 15 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e15861
Antigenicity of proteins in cooked egg powder and skim milk powder for children with egg and milk allergies
- 15 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e15861
Antigenicity of proteins in cooked egg powder and skim milk powder for children with egg and milk allergies
- Open Access
- 9 October 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (4) , 201-204
A case of white bean allergy
White bean allergy is uncommon and rarely reported. Herein, we report a case of white bean allergy in a patient with Down syndrome. A 7-year-old girl with Down syndrome experienced allergic symptoms twice after eating white bean and visited our hospital for a food allergy investigation. An ImmunoCAP assay revealed a white bean-specific IgE (13.4 kUA/L) in the patient’s serum. In addition, her skin prick test result was positive. Moreover, ingestion of 2 g of boiled white beans in an oral food challenge test induced intermittent cough, desaturation, generalized urticaria, abnormal sleep, and mild hypotension. Thus, we diagnosed the patient with white bean allergy. We performed western blotting and mass spectrometric analysis and detected the following allergens: Phytohemagglutinin, group 3 late embryogenesis abundant protein, lipoxygenase, and legumin. In addition, we detected several candidate allergenic proteins for the first time. White bean, runner bean, or azuki bean was considered the primary source of sensitization because although immunoblotting inhibition tests revealed that the abovementioned beans inhibited other legumes, soybean, which she tolerates, showed little inhibition of the other legumes. However, we could not confirm whether the patient could ingest legumes other than soybean or white bean because her family did not wish to continue with further testing. This is the first report of a case of systemic allergic reactions to white bean in a child with Down syndrome. Further studies are needed to identify white bean allergens and understand the relationship between Down syndrome and white bean allergy.
- 9 October 2023
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (4) , 201-204
Open AccessA case of white bean allergy
White bean allergy is uncommon and rarely reported. Herein, we report a case of white bean allergy in a patient with Down syndrome. A 7-year-old girl with Down syndrome experienced allergic symptoms twice after eating white bean and visited our hospital for a food allergy investigation. An ImmunoCAP assay revealed a white bean-specific IgE (13.4 kUA/L) in the patient’s serum. In addition, her skin prick test result was positive. Moreover, ingestion of 2 g of boiled white beans in an oral food challenge test induced intermittent cough, desaturation, generalized urticaria, abnormal sleep, and mild hypotension. Thus, we diagnosed the patient with white bean allergy. We performed western blotting and mass spectrometric analysis and detected the following allergens: Phytohemagglutinin, group 3 late embryogenesis abundant protein, lipoxygenase, and legumin. In addition, we detected several candidate allergenic proteins for the first time. White bean, runner bean, or azuki bean was considered the primary source of sensitization because although immunoblotting inhibition tests revealed that the abovementioned beans inhibited other legumes, soybean, which she tolerates, showed little inhibition of the other legumes. However, we could not confirm whether the patient could ingest legumes other than soybean or white bean because her family did not wish to continue with further testing. This is the first report of a case of systemic allergic reactions to white bean in a child with Down syndrome. Further studies are needed to identify white bean allergens and understand the relationship between Down syndrome and white bean allergy.
- Open Access
- 8 April 2023
- Published by Elsevier in Allergology International
- Vol. 72 (4) , 604-606
Allergic reaction to Hyperlasion Schmitz (Diptera: Sciaridae)
- 8 April 2023
- Published by Elsevier in Allergology International
- Vol. 72 (4) , 604-606
Open AccessAllergic reaction to Hyperlasion Schmitz (Diptera: Sciaridae)
- Open Access
- 20 February 2023
- Published by Elsevier in Allergology International
- Vol. 72 (3) , 488-490
Serine phosphate group in casein phosphopeptide is crucial for IgE binding to αs1-casein
- 20 February 2023
- Published by Elsevier in Allergology International
- Vol. 72 (3) , 488-490
Open AccessSerine phosphate group in casein phosphopeptide is crucial for IgE binding to αs1-casein